Biomarkers · Endocrine
Prolactin
Lower values go with lower risk of death. Not measured in our NHANES panel. The curve is drawn from the published study (source below).
Prolactin and risk of death
Published curve higher than the NHANES fitNHANES fit higher
Risk of death relative to the curve's reference value, drawn from the published study (source below).
What studies found when this marker was changed
They describe what happened in those study groups, not a recommendation. See all catalogued interventions.
Measured changes in Prolactin, study by study
4 effects with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Green points move the marker the way lower risk of death lies; amber the other way. Study results in the groups studied, not predictions for a person.
| Type | Intervention | Reported effect | Evidence | Source |
|---|---|---|---|---|
| pharmacologic | Adding aripiprazole 5 mg daily to ongoing antipsychotic treatment in patients with antipsychotic-induced prolactin >50 ng/mL | Prolactin lowered by 64.26 ng/mL (95% CI 41.37-87.00) with adjunctive aripiprazole 5 mg in patients with prolactin >50 ng/mL; 10 mg -59.81, >10 mg -68.01 | meta-analysis | Lu Z, Sun Y, Zhang Y, et al. Pharmacological treatment strategies for… |
Things that worsen it
| Type | Condition or exposure | Reported effect | Evidence | Source |
|---|---|---|---|---|
| pharmacologic | Oral paliperidone for acute multi-episode schizophrenia (network meta-analysis of 32 antipsychotics vs placebo) | Prolactin 48.51 ng/mL higher than placebo (95% CrI 43.52-53.51), the largest elevation of 32 antipsychotics; clozapine -77.05 ng/mL | meta-analysis | Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and… |
| pharmacologic | Risperidone or paliperidone for neuropsychiatric/neurodevelopmental conditions in people under 18 (median 7 weeks of treatment) | Prolactin 26.40 ng/mL higher than placebo (95% CI 21.13-31.67) with risperidone/paliperidone, vs -2.83 ng/mL with aripiprazole | meta-analysis | Rogdaki M, McCutcheon RA, D'Ambrosio E, et al. Comparative physiological… |
What else moves this marker
They describe those study groups, not an individual, and an association is not a cause.
Diseases and conditions
| What | Effect on the marker | Comparison · population | Source |
|---|---|---|---|
| ↑ Systemic sclerosis · patients with systemic sclerosis vs healthy controls | SMD +1 (95% CI 0.56 to 1.43) | systemic sclerosis patients vs healthy controls · 293 patients with systemic sclerosis and 282 controls (9 studies) | meta analysis · PMID 32957368 |
Sources
- Risk curve: Papazoglou 2024 (PMID 38366650): all-cause HR 1.81 (1.43-2.3) highest vs lowest PRL category (study-specific categories). Scaled to published population values.
- Papazoglou et al. Serum Prolactin Levels and Mortality in Adults Without Prolactinoma: A Meta-Analysis. The Journal of clinical endocrinology and metabolism. 2024;109:e1652-e1664.
Map Prolactin against another biomarker.
Related markers: Estradiol (17beta-Estradiol) · Follicle-Stimulating Hormone (FSH) · Growth Hormone (GH) · Serum Leptin · Thyroxine (Total T4)